Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 170

1.

Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC).

Rossi L, Vakiarou F, Zoratto F, Bianchi L, Papa A, Basso E, Verrico M, Lo Russo G, Evangelista S, Rinaldi G, Perrone-Congedi F, Spinelli GP, Stati V, Caruso D, Prete A, Tomao S.

Cancer Manag Res. 2013 Nov 19;5:377-85. doi: 10.2147/CMAR.S47986. Review.

2.

Real-world impact of education: treating patients with ipilimumab in a community practice setting.

Ledezma B, Heng A.

Cancer Manag Res. 2013 Dec 21;6:5-14. doi: 10.2147/CMAR.S52543. Review.

3.

Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab.

Sorscher S.

Cancer Manag Res. 2013 Dec 11;9:1-3. doi: 10.2147/CMAR.S55091. eCollection 2013.

4.

Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel.

Bensadoun RJ, Humbert P, Krutman J, Luger T, Triller R, Rougier A, Seite S, Dreno B.

Cancer Manag Res. 2013 Dec 9;5:401-8. doi: 10.2147/CMAR.S52256. eCollection 2013.

5.

Personalized treatment for advanced colorectal cancer: KRAS and beyond.

Patel GS, Karapetis CS.

Cancer Manag Res. 2013 Nov 21;5:387-400. doi: 10.2147/CMAR.S35025. eCollection 2013. Review.

6.

The claudin family of proteins in human malignancy: a clinical perspective.

Ding L, Lu Z, Lu Q, Chen YH.

Cancer Manag Res. 2013 Nov 8;5:367-75. doi: 10.2147/CMAR.S38294. Review.

7.

Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety.

Welker MW, Trojan J.

Cancer Manag Res. 2013 Oct 8;5:337-47. doi: 10.2147/CMAR.S35029. Review.

8.

Benefit risk assessment and update on the use of docetaxel in the management of breast cancer.

Alken S, Kelly CM.

Cancer Manag Res. 2013 Oct 14;5:357-65. doi: 10.2147/CMAR.S49321. Review.

9.

Prospective study evaluating the radiosensitizing effect of reduced doses of temozolomide in the treatment of Egyptian patients with glioblastoma multiforme.

Gaber M, Selim H, El-Nahas T.

Cancer Manag Res. 2013 Oct 8;5:349-56. doi: 10.2147/CMAR.S52147. eCollection 2013.

10.

The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival.

Tantraworasin A, Saeteng S, Lertprasertsuke N, Arayawudhikul N, Kasemsarn C, Patumanond J.

Cancer Manag Res. 2013 Oct 3;5:327-36. doi: 10.2147/CMAR.S52073. eCollection 2013.

11.

Focal low-dose rate brachytherapy for the treatment of prostate cancer.

Tong WY, Cohen G, Yamada Y.

Cancer Manag Res. 2013 Sep 13;5:315-25. doi: 10.2147/CMAR.S33056. eCollection 2013. Review.

12.

Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.

Chao MP.

Cancer Manag Res. 2013 Aug 23;5:251-69. doi: 10.2147/CMAR.S34273. eCollection 2013. Review.

13.

Critical appraisal of the potential use of cannabinoids in cancer management.

Cridge BJ, Rosengren RJ.

Cancer Manag Res. 2013 Aug 30;5:301-13. doi: 10.2147/CMAR.S36105. eCollection 2013. Review.

14.

Perspectives on the immunologic microenvironment of astrocytomas.

Hewedi IH, Radwan NA, Shash LS, Elserry TH.

Cancer Manag Res. 2013 Aug 30;5:293-9. doi: 10.2147/CMAR.S48942. eCollection 2013.

15.

3-Phosphoinositide-dependent protein kinase-1 as an emerging target in the management of breast cancer.

Fyffe C, Falasca M.

Cancer Manag Res. 2013 Aug 23;5:271-80. doi: 10.2147/CMAR.S35026. eCollection 2013. Review.

16.

Targeting CD19 in B-cell lymphoma: emerging role of SAR3419.

Raufi A, Ebrahim AS, Al-Katib A.

Cancer Manag Res. 2013 Aug 27;5:225-33. doi: 10.2147/CMAR.S45957. eCollection 2013. Review.

17.

AKT-independent PI3-K signaling in cancer - emerging role for SGK3.

Bruhn MA, Pearson RB, Hannan RD, Sheppard KE.

Cancer Manag Res. 2013 Aug 26;5:281-92. doi: 10.2147/CMAR.S35178. eCollection 2013. Review.

18.

Isolated limb infusion chemotherapy for melanoma: an overview of early experience at the Adelaide Melanoma Unit.

Giles MH, Coventry BJ.

Cancer Manag Res. 2013 Aug 20;5:243-9. doi: 10.2147/CMAR.S45746. eCollection 2013.

19.

The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective.

Creighton CJ, Gibbons DL, Kurie JM.

Cancer Manag Res. 2013 Jul 31;5:187-95. doi: 10.2147/CMAR.S35171. eCollection 2013.

20.

Supplemental Content

Loading ...
Support Center